AKT1 is altered in 5.01% of breast adenocarcinoma patients [2].

AKT1 is an inclusion eligibility criterion in 1 clinical trial for breast adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains AKT1 status and breast adenocarcinoma as inclusion criteria, 1 is phase 3 (1 open) [3].

BRCA1 is altered in 2.89% of breast adenocarcinoma patients [2].

BRCA1 is an inclusion eligibility criterion in 1 clinical trial for breast adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains BRCA1 status and breast adenocarcinoma as inclusion criteria, 1 is phase 2 (0 open) [3].

BRCA2 is altered in 4.13% of breast adenocarcinoma patients [2].

BRCA2 is an inclusion eligibility criterion in 1 clinical trial for breast adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains BRCA2 status and breast adenocarcinoma as inclusion criteria, 1 is phase 2 (0 open) [3].

ERBB2 is altered in 13.55% of breast adenocarcinoma patients [2].

ERBB2 is an inclusion eligibility criterion in 10 clinical trials for breast adenocarcinoma, of which 9 are open and 1 is closed. Of the trials that contain ERBB2 status and breast adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open), 8 are phase 2 (7 open), and 1 is phase 3 (1 open) [3].

ESR1 is altered in 7.13% of breast adenocarcinoma patients [2].

ESR1 is an inclusion eligibility criterion in 1 clinical trial for breast adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains ESR1 status and breast adenocarcinoma as inclusion criteria, 1 is phase 3 (1 open) [3].

KRAS is altered in 1.94% of breast adenocarcinoma patients [2].

KRAS is an inclusion eligibility criterion in 1 clinical trial for breast adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS status and breast adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

PIK3CA is altered in 36.8% of breast adenocarcinoma patients [2].

PIK3CA is an inclusion eligibility criterion in 2 clinical trials for breast adenocarcinoma, of which 2 are open and 0 are closed. Of the trials that contain PIK3CA status and breast adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 3 (1 open) [3].

PTEN is altered in 7.11% of breast adenocarcinoma patients [2].

PTEN is an inclusion eligibility criterion in 1 clinical trial for breast adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and breast adenocarcinoma as inclusion criteria, 1 is phase 3 (1 open) [3].